Felix fossheim

[Felix fossheim @felix_fossheim]

@WallStSai @ResearchPulse1 3rd gen snac

[Felix fossheim @felix_fossheim]

@WallStSai @ResearchPulse1 I would rather purchase viking if I had to choose. I can only imagine the potential for oral vk2735 with novos third generation already in place.

[Felix fossheim @felix_fossheim]

@WallStSai @ResearchPulse1 Personally I would rather focus on trying to make Efruxifermin an oral option with snac. A shorter plasma trial to make it orally could save a lot of money for novo. In addition it could be added to zena or sema.

[Felix fossheim @felix_fossheim]

@WallStSai @ResearchPulse1 Not 2,4 / 25 mg. It’s about the same wl, corresponding effects and blood levels of Sema. Making it essentially the same.

[Felix fossheim @felix_fossheim]

@RVADreams73 @ResearchPulse1 @JCanNuSH Ip theft is simply the problem here. Drugs will go generic eventually, but the current price is what’s driving innovation and the insentivs to make new and better drugs.

[Felix fossheim @felix_fossheim]

@BigBeedaBig @bioinvestor24 This is why your not running a big company and he is. Everything can be a bad purchase if you pay to much. And current sp does not signal what a buyout may be priced at

[Felix fossheim @felix_fossheim]

@LAlbertsen66721 @fastmoney911 @investseekers I bought more since i believed it was overdone, however the guidance was as good as any. In fact it would probably be better if they just did not guide. And there were no «wonder news». The cagrisema trail could be bad, as it looks, increasing dose does not mean better wl.

[Felix fossheim @felix_fossheim]

@LordWhats @investseekers Nobody uses this as a metric, if they have cf of 30 b and buys ma for 10 fcf is then 20. makes no sense to state it that way

[Felix fossheim @felix_fossheim]

@fastmoney911 @investseekers its normal in pharma, lly azn pfz all have their moments like this

[Felix fossheim @felix_fossheim]

@LordWhats @investseekers FCF and ma? does not work that way

[Felix fossheim @felix_fossheim]

@ObsvRetardation @avidresearch @JCanNuSH 1 fckn person yhe

[Felix fossheim @felix_fossheim]

@ObsvRetardation @woidebaben @bioinvestor24 The retard keeps retarding I guess. Novo has plenty of time before they need to make an offer, even if the maintenance trail data is released soon.

[Felix fossheim @felix_fossheim]

@girandoni @bioinvestor24 @woidebaben With lly? Hahah

[Felix fossheim @felix_fossheim]

@ResearchPulse1 @bioinvestor24 Regardless, the peptide will only be sucsessfull if its tolarable, we already know its very efficacious. Mby sutible for oral?

[Felix fossheim @felix_fossheim]

@ObvsRetardation I just hate people complaining, especially if they are now better. Again you fit right in

[Felix fossheim @felix_fossheim]

@ObvsRetardation I don’t know how one could advertise a short position better then you…. Like stfu

[Felix fossheim @felix_fossheim]

@BarnyardBull72 This is a perfect example of how oral peptides is almost impossible to get right. Zena and Sema will arguably reach 5% potency and will be suitable for decades to come, this with just snac.

[Felix fossheim @felix_fossheim]

@vijverberg @Redpulse_News fackin hell, 17 vs 12 %? same price, novo has more capasity then ever before